HCSP's conference coverage of AASLD 2010 is winding down, but be sure to check out what we have posted so far in the data on the DAA's (Direct Acting Antiviral Agents). It was an amazing conference this year–over 30 new DAA's were presented along with extensive information on telaprevir and boceprevir.
We also posted our monthly HBV Journal Review for November–of special interest is a story on Occult Hepatitis B infection. Occult or hidden HBV infection is a very real concern for people with HCV since it is believed that many people with HCV have occult HBV infection and it increases general liver disease progression and lowers HCV treatment response. Other newsworthy items include treatment data on tenofovir, the effect of coffee consumption, AFP levels and liver cancer, and much, much more.
We have also updated many of our fact sheets such as our Transmission and Prevention fact sheets, HCV in African Americans and Latinos (with information about the dramatic increases in treatment response rates with the new DAA's) and we have updated our Telaprevir HCV Fact Sheet to include information about treatment responses in African Americans, Hispanics and people with severe fibrosis/cirrhosis.
We also continue to bring you news stories usually on a daily basis.
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org
**Questions and Comments: Questions and/or comments can be directed to firstname.lastname@example.org
**To receive the eblast in your email inbox simply send an e-mail to: email@example.com with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.